Increased immunogenicity of tumor vaccines complexed with anti-gal: Studies in knockout mice for α1,3galactosyltransferase

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3417-3423

  LaTemple, Denise C ^a   Abrams, J Todd ^a   Zhang, Shu Yun ^a   Galili, Uri ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE; GALACTOSYLTRANSFERASE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; COMPLEX FORMATION; IMMUNOGENICITY; KNOCKOUT MOUSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES; GALACTOSE; GALACTOSYLTRANSFERASES; GLYCOSYLATION; IMMUNOGLOBULIN G; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0033565256     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Maass, G., Schmidt, W., Berger, M., Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M. L., and Schweighoffer, T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA, 92: 5540-5544, 1995.
2. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow derived cells in presenting class I restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
3. Schweighoffer, T., Schmidt, W., Buschle, M., and Birnstiel, M. L. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines. Gene Ther., 3: 819-824, 1996.
4. Zinkemagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kundig, T., and Hengartner, H. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev., 156: 199-209, 1997.
5. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., and Nadler, L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84: 3261-3282, 1994.
6. Schwarz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 71: 1065-1068, 1992.
7. Pardoll, D. M. Cancer vaccines. Immunol. Today, 14: 310-316, 1993.
8. Old, L. J. Immunotherapy of cancer. Sci. Am., Sept.: 136-143, 1996.
9. Chen, L., Ashe, S, Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsly, P. S. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T-lymphocyte molecule CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
10. Zitvogel, L., Mayordoma, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
11. Nair, S. K., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer, 17: 706-715, 1997.
12. Askely, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., and Gilboa, E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med., 186: 1177-1190, 1997.
13. Galili, U., and LaTemple, D. C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol. Today, 18: 281-285, 1997.
14. LaTemple, D. C., Henion, T. R., Anaraki, F., and Galili, U. Synthesis of α-galactosyl epitopes by recombinant α1,3galacotysltransferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res., 56: 3069-3074, 1996.
15. Gosselin, E. J., Wardwell, K., Gosselin, D. R., Alter, N., Fisher, J. L., and Guyre, P. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol., 149: 3477-3481, 1992.
16. Manca, F., Fenoglio, D., LiPira, G., Kunkl, A., and Celada, F. Effect of antigen/ antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med., 173: 37-48, 1991.
17. Celis, E., and Chang, T. W. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science (Washington DC), 224: 297-299, 1984.
18. Celis, E., Abraham, K. G., and Miller, R. W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology, 7: 563-568, 1987.
19. Liu, C., Gosselin, E. J., and Guyre, P. M. Fcγ RII on human B cells can mediate enhanced antigen presentation. Cell. Immunol,. 167: 188-194, 1996.
20. Galili, U., Rachmilewitz, E. A., Peleg, A., and Flechner, I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J. Exp. Med., 160: 1519-1531, 1984.
21. Galili, U., Macher, B. A., Buehler, J., and Shohet, S. B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α-(1,3)-linked galactose residues. J. Exp. Med., 162: 573-582, 1985.
22. Galili, U., Buehler, J., Shohet, S. B., and Macher, B. A. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J. Exp. Med., 165: 693-704, 1987.
23. Galili, U., Shohet, S. B., Kobrin, E., Stults, C. L. M., and Macher, B. A. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem., 263: 17755-17762, 1988.
24. Galili, U., Clark, M. R., Shohet, S. B., Buehler, J., and Macher, B. A. Evolutionary relationship between the anti-Gal antibody and the Galα1,3Gal epitope in primates. Proc. Natl. Acad. Sci. USA, 84: 1369-1373, 1987.
25. Galili, U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol. Today, 14: 480-482, 1993.
26. Sandrin, M., Vaughan, H. A., Dabkowski, P. L., and McKenzi, I. F. C. Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc. Natl. Acad. Sci. USA, 90: 11391-11395, 1993.
27. Collins, B. H., Cotterell, A. H., McCurry, K. R., Alvarado, C. G., Magee, J. C., Parker, W., and Platt, J. L. Cardiac xenografts between primate species provide evidence for the importance of α-galactosyl determinant in hyperacute rejection. J. Immunol., 154: 5500-5510, 1995.
28. Rother, R. P., Foder, W. L., Springhorn, J. P., Birks C. W., Setter E., Sandrin M. S., Squinto S. P., and Rollins S. A. A novel mechanism of retrovirus inactivation in human serum mediated by α-galactosyl natural antibody. J. Exp. Med., 182: 1345-1355, 1995.
29. Takeuchi, Y., Porter, C. D., Strahan, K. M., Peerce, A. F., Gustafsson, K., Cosset, J. L., Weiss, R. A., and Collins, M. K. L. Sensitization of cells and retroviruses to human serum by α1-3galactosyltransferase. Nature (Lond.), 379: 85-89, 1996.
30. Rother R. P., and Squinto S. P. The α-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell, 86: 185-188, 1996.
31. Larsen, R. D., Rajan, V. P., Ruff, M., Kukowska-Latallo, J., Cummings, R. D., and Lowe, J. B. Isolation of a cDNA encoding murine UDP galactose: βD-galactosyl-1,4-N-acetyl-D-glucosamine α1,3-galactosyltransferase: expression cloning by gene transfer. Proc. Natl. Acad. Sci. USA, 86: 8227-8231, 1989.
32. Joziasse, D. H., Shaper, N. L., Kim, D., Van den Eijnden, D. H., and Shaper, J. H. Murine α1,3galactosyltransferase. A simple gene locus specifies four isoforms of the enzyme by alternative splicing. J. Biol. Chem., 267: 5543-5541, 1992.
33. Thall, A. D., Maly, P., and Lowe, J. B. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J. Biol. Chem., 270: 21437-21440, 1995.
34. Thall, A. D., Murphy, H. S., and Lowe, J. B. α1,3galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant. Proc., 28: 556-557, 1996.
35. LaTemple, D. C., and Galili, U. Adult and neonatal anti-Gal response in knock-out mice for α-galactosyltransferase. Xenotransplantation, 5: 191-196, 1998.
36. Arca, M. J., Krauss, J. C., Strome, S. E., Cameron, M. J., and Chang, A. E. Diverse manifestations of lumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol. Immunother., 42: 237-245, 1996.
37. Gorelik, E., Peppoloni, S., Overton, R., and Herberman, R. B. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N-nitronitroso-guanidine. Cancer Res., 45: 5341-5347, 1985.
38. h gene: immunological and nonimmunological mechanisms. Clin. Exp. Metastasis, 11: 439-452, 1993.
39. Kim, M., Rao, M. V., Tweardy, D. J., Prakash, M., Galili, U., and Gorelik, E. Lectin induced apoptosis of tumor cells. Glycobiology, 3: 447-453, 1993.
40. Hart, I. R. The selection and characterization of an invasive variant of the BL6 melanoma. Am. J. Pathol., 97: 587-600, 1979.
41. Gorelik, E., Duty, L., Anaraki, F., and Galili, U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3galactosyltransferase gene transfection. Cancer Res., 55: 4168-4173, 1995.
42. Galili, U., LaTemple, D. C., and Radic, M. Z. A sensitive assay for measuring α-gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation, 65: 1129-1132, 1998.
43. Eto, T., Iichikawa, Y., Nishimura, K., Ando, S., and Yamakawa, T. Chemistry of lipids of the posthemolytic residue or stroma of erythrocytes. XVI. Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes in rabbit. J. Biochem., 64: 205-213, 1968.
44. Stellner, K., Saito, H., and Hakomori, S. I. Determination of aminosugar linkage in glycolipids by methylation. Aminosugar linkage of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch. Biochem. Biophys., 155: 464-472, 1973.
45. Armstrong, C. A., Boteila, R., Galloway, T. H., Murray, N., Kramp, J. M., Song, I. S., and Ansel, J. C. Anti-tumor effect of granulocyte-macrophage colony-stimulating factor production by melanoma. Cancer Res., 56: 2191-2198, 1996.
46. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
47. Simon, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owen, A. H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshall, F. F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by in vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 37: 1537-1546, 1997.
48. Hosokawa, M., Okayasu, T., Ikeda, K., Katoh, H., Suzuki, Y., and Kobayashi, H. Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells. Cancer Res., 43: 2301-2305, 1983.
49. Sugiura, C., Itaya, T., Kondoh, N., Kuzumaki, N., Takeichi, N., Hosokawa, M., and Kobayashi, H. Xenogenization of tumor cells by transfection with plasmid containing env gene of Friend leukemia virus. Jpn. J. Cancer Res., 79: 1259-1263, 1988.
50. Berd, D., Maguire H. C., and Mastrangelo M. J. Treatment of human melanomas with a hapten-modified autologous vaccine. Ann. N. Y. Acad. Sci., 690: 147-152, 1993.